Skip to main content

VR Adviser, LLC

SEC CIK
0001615982
Latest filing
Aug 14, 2026

Holdings in Q2 2026

Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.

Institution overview
Positions
33
0 vs. Q1 2026
Portfolio value
$3.30B
+$618.9M (+23.1%) vs. Q1 2026
Filed
Aug 14, 2026
SEC
Holdings of VR Adviser, LLC in Q2 2026
SecurityClassSharesValue% of portfolioShare changeActionHistory
APGEApogee Therapeutics, Inc.COM8,493,321$1.13B34.2%00.0%UnchangedHistory
ORKAOruka Therapeutics, Inc.COM4,148,428$394.8M12.0%00.0%UnchangedHistory
ERASErasca, Inc.COM17,891,812$327.8M9.9%+1,509,000+9.2%AddedHistory
SYRESpyre Therapeutics, Inc.COM NEW2,985,448$265.0M8.0%−700,000−19.0%ReducedHistory
DNTHDianthus Therapeutics, Inc.COM1,180,000$115.0M3.5%00.0%UnchangedHistory
OCULOcular Therapeutix, IncCOM10,346,926$101.6M3.1%00.0%UnchangedHistory
DMRADamora Therapeutics, Inc.COM NEW3,603,595$93.7M2.8%00.0%UnchangedHistory
SVRASavara IncCOM14,745,943$90.8M2.8%+1,005,568+7.3%AddedHistory
JBIOJade Biosciences, Inc.COM NEW3,220,364$71.6M2.2%00.0%UnchangedHistory
COGTCogent Biosciences, Inc.COM1,642,166$63.6M1.9%−357,834−17.9%ReducedHistory
VRDNViridian Therapeutics, Inc.COM3,257,917$59.8M1.8%−624,792−16.1%ReducedHistory
VORVor Biopharma Inc.COM NEW3,041,719$56.0M1.7%00.0%UnchangedHistory
DYNDyne Therapeutics, Inc.COM2,173,913$48.3M1.5%00.0%UnchangedHistory
MAZEMaze Therapeutics, Inc.COM1,602,034$47.8M1.4%00.0%UnchangedHistory
RLMDRelmada Therapeutics, Inc.COM6,844,305$47.4M1.4%+2,000,925+41.3%AddedHistory
ORICOric Pharmaceuticals, Inc.COM4,319,765$46.8M1.4%00.0%UnchangedHistory
CBIOCrescent Biopharma, Inc.COM2,133,576$38.4M1.2%00.0%UnchangedHistory
ZURAZura Bio LtdCLASS A ORD SHS6,434,990$38.0M1.2%00.0%UnchangedHistory
ANLAdlai Nortye Group Ltd.ADS3,212,731$36.9M1.1%00.0%UnchangedHistory
ELVNEnliven Therapeutics, Inc.COM526,331$26.7M0.8%−1,200,000−69.5%ReducedHistory
HELPCybin Inc.COM NEW3,851,654$25.5M0.8%00.0%UnchangedHistory
CGEMCullinan Therapeutics, Inc.COM1,379,965$25.1M0.8%00.0%UnchangedHistory
IPSCCentury Therapeutics, Inc.COM8,695,652$21.3M0.6%00.0%UnchangedHistory
ARTVArtiva Biotherapeutics, Inc.COM2,043,596$19.8M0.6%+434,027+27.0%AddedHistory
CTMXCytomX Therapeutics, Inc.COM4,982,124$18.7M0.6%−5,000,000−50.1%ReducedHistory
ACHVAchieve Life Sciences, Inc.COM2,751,032$18.0M0.5%+2,751,032NewHistory
PBLSParabilis Medicines, Inc.Stock625,000$17.1M0.5%+625,000NewHistory
SRZNSurrozen, Inc.COM NEW632,931$16.4M0.5%00.0%UnchangedHistory
KRROKorro Bio, Inc.COM1,009,500$13.3M0.4%00.0%UnchangedHistory
ANROAlto Neuroscience, Inc.COM SHS500,000$13.2M0.4%00.0%UnchangedHistory
XFORX4 Pharmaceuticals, IncCOM NEW1,934,253$9.03M0.3%+1,603,728+485.2%AddedHistory
RACCResearch Alliance Corp IIIORD SHS CL A300,000$3.21M0.1%+300,000NewHistory
INMInMed Pharmaceuticals Inc.Common Stock32,685$50.7K<0.1%+32,685NewHistory

Sold out since Q1 2026 (4)

Positions held at the end of Q1 2026 that are gone from this filing.

Positions of VR Adviser, LLC sold out since Q1 2026
SecurityClassShares in Q1 2026Value in Q1 2026% of portfolio in Q1 2026History
KALVKalVista Pharmaceuticals, Inc.COM6,474,485$130.3M4.9%History
ENGNenGene Therapeutics Inc.COM4,771,414$32.5M1.2%History
TENXTenax Therapeutics, Inc.COM NEW1,675,262$26.8M1.0%History
SEPNSepterna, Inc.COM506,056$12.2M0.5%History